eMJA     The Medical Journal of Australia

Home | Issues | eMJA shop | My account | Classifieds | Contact | More... | Topics | Search   

 Previous | Next 

→ Contents list for this issue

→ More articles on Emergency medicine

→ Search PubMed for related articles

Click to Login

Hide the Login Box

Login
If you are registered with the eMJA, your username is the email address you have provided.
AMA members can login using their AMA username and password.

→ Register for free access if you don't have an account

Matters Arising

Tissue plasminogen activator for acute ischaemic stroke

Julia J Batmanian, Meeyin Lam, Caitlin Matthews, Andrew Finckh, Martin Duffy, Robert Wright, Bruce J Brew and Romesh Markus
MJA 2008; 188 (8): 489-490

In reply: We welcome the opportunity to respond to issues raised by Hurley and Toncich. Australian, United States and European stroke guidelines based on level 1, grade A evidence recommend intravenous recombinant tissue plasminogen activator (IV-rtPA) for patients with acute ischaemic stroke (AIS) who meet specific inclusion criteria and present within 3 hours of AIS onset.1,2 Recombinant tPA is approved for this indication by the Therapeutic Goods Administration.

Home | Issues | eMJA shop | My account | Classifieds | More... | Contact | Topics | Search

The Medical Journal of Australia    eMJA  

©The Medical Journal of Australia 2008 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377